Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab vs Golimumab in PsA TNF-IR Patients (EVOLUTION)
NCT05669833Phase 3Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jul 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab in psoriatic arthritis (PsA), sponsored by University of Pennsylvania. Started Jul 2023; status: recruiting.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05669833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669833.